Oxytocin and Ejaculation

Oxytocin (OT) – the nine-amino-acid neuropeptide most associated with birth and bonding – plays a pivotal yet underappreciated role in male sexual physiology, particularly in the ejaculatory reflex. Over four decades of research have established that oxytocin concentrations surge during orgasm, that oxytocinergic neurones project to spinal ejaculatory centres, and that pharmacological manipulation of oxytocin signalling can alter ejaculatory latency in both animal models and humans. This article reviews the neuroendocrine mechanisms by which oxytocin modulates ejaculation, the evidence from plasma measurement studies, and the emerging clinical implications for disorders of ejaculatory function.

Neuroanatomy of the Ejaculatory Reflex

The Spinal Ejaculatory Generator

Ejaculation is a two-phase reflex comprising emission (propulsion of seminal fluid into the posterior urethra via contractions of the vas deferens, seminal vesicles, and prostate) and expulsion (rhythmic contractions of the bulbospongiosus and ischiocavernosus muscles that expel semen from the urethra). The spinal generator for ejaculation (SGE) resides in the lumbar spinothalamic (LSt) cells at spinal cord levels L3–L4 in the rat, with a likely homologous region in humans (Truitt & Coolen, 2002).

The SGE integrates peripheral sensory input from the dorsal nerve of the penis with descending commands from supraspinal centres – principally the medial preoptic area (MPOA), the paraventricular nucleus (PVN) of the hypothalamus, and the nucleus paragigantocellularis (nPGi) of the brainstem (Coolen et al., 2004). It is through the PVN that oxytocin enters the ejaculatory circuitry.

Oxytocinergic Projections from the PVN

The PVN contains both magnocellular neurones (projecting to the posterior pituitary for systemic OT release) and parvocellular neurones (projecting to the spinal cord and brainstem). Tract-tracing studies in rats have demonstrated direct oxytocinergic projections from parvocellular PVN neurones to the lumbosacral spinal cord, where they terminate in proximity to motor neurones innervating the bulbospongiosus muscle (Argiolas & Melis, 2004). These projections represent the anatomical substrate for oxytocin’s pro-ejaculatory effects.

Intrathecal injection of oxytocin at the L4–L5 level in male rats produces seminal emission and ejaculation-like penile contractions in the absence of sexual stimulation, confirming a direct spinal site of action (Giuliano et al., 2001). This effect is abolished by pre-treatment with the selective oxytocin receptor antagonist d(CH₂)₅[Tyr(Me)²,Orn⁸]-vasotocin, demonstrating receptor specificity.

Oxytocin Release During Male Sexual Response

Plasma Oxytocin Surges at Orgasm

The seminal study by Carmichael et al. (1987) established that plasma oxytocin concentrations rise significantly during sexual arousal in men and peak sharply at orgasm. Using serial blood sampling during self-stimulation to orgasm, they demonstrated a three- to five-fold increase in plasma OT from baseline (~2 pg/mL) to orgasmic peak (~8–12 pg/mL), with a rapid decline within 5 minutes post-ejaculation.

Murphy et al. (1987) replicated these findings, confirming the orgasm-specific OT surge and demonstrating that it occurs independently of the concurrent rise in plasma vasopressin (AVP). Importantly, OT levels did not rise significantly during arousal without orgasm, suggesting that the hormone release is coupled specifically to the ejaculatory reflex rather than to sexual excitation per se.

More recent work using improved immunoassay techniques has refined these observations. Blaicher et al. (1999) reported mean orgasmic OT peaks of 25.6 pg/mL in healthy men – substantially higher than earlier estimates – and showed that the OT surge correlates positively with subjective orgasm intensity and with the volume of ejaculate produced. Ogawa et al. (2017) confirmed elevated salivary oxytocin post-orgasm, providing a non-invasive corroboration of the plasma findings.

Central Versus Peripheral OT Release

The plasma OT measured peripherally reflects pituitary secretion from magnocellular neurones. However, the pro-ejaculatory effects of oxytocin are primarily mediated by central release from parvocellular PVN neurones projecting to spinal motor circuits. Central and peripheral release can occur in parallel but are semi-independently regulated (Ludwig & Leng, 2006). This dual-release model – sometimes called the “cuddle hormone” paradox in popular literature – explains why peripheral OT levels correlate with orgasm intensity but do not themselves drive ejaculation.

Cerebrospinal fluid (CSF) OT measurements in animal models show that central OT release during mating is quantitatively greater and temporally more sustained than peripheral release, supporting the primacy of the central pathway in ejaculatory control (Hughes et al., 1987).

Mechanisms of Oxytocin Action on Ejaculation

Spinal Motor Neurone Facilitation

At the spinal level, oxytocin acts on OXTR expressed on motor neurones of the Onuf’s nucleus (in humans) and the spinal nucleus of the bulbocavernosus (SNB, in rodents). OXTR activation increases neuronal excitability through Gq-coupled phospholipase C signalling, raising intracellular calcium and reducing after-hyperpolarisation – effects that lower the firing threshold for the coordinated bursts of motor neurone activity that produce the rhythmic expulsive contractions of ejaculation (Veronneau-Longueville et al., 1999).

Smooth Muscle Contraction in the Reproductive Tract

Oxytocin receptors are expressed in the smooth muscle of the epididymis, vas deferens, prostate, and seminal vesicles (Frayne & Nicholson, 1998). OT stimulates contractions in these structures, facilitating sperm transport during the emission phase. In vitro studies show that oxytocin increases the contractile amplitude of isolated human vas deferens preparations in a dose-dependent manner, an effect blocked by atosiban (Filippi et al., 2002). This peripheral action of oxytocin on the reproductive tract smooth muscle complements its central pro-ejaculatory effects. For the relationship between oxytocin and penile erection, see our companion article.

Interaction with Other Neurotransmitter Systems

Oxytocin does not act in isolation. Within the PVN and spinal cord, oxytocinergic neurones interact with:

• Serotonin (5-HT): Descending serotonergic projections from the nucleus paragigantocellularis exert tonic inhibition on the SGE. SSRIs delay ejaculation by enhancing this inhibitory tone. OT may partially counteract serotonergic inhibition by directly exciting spinal motor neurones, providing a mechanistic basis for why some men on SSRIs retain ejaculatory function (de Jong et al., 2007).
• Dopamine: Dopaminergic input from the incertohypothalamic A13 cell group activates PVN oxytocinergic neurones. The pro-sexual effects of apomorphine and other dopamine agonists are mediated in part through this OT pathway (Melis & Argiolas, 2011).
• Nitric oxide (NO): NO acts as a retrograde messenger within the PVN, facilitating OT release during sexual arousal. nNOS-knockout mice exhibit impaired ejaculatory function and reduced OT release (Melis & Argiolas, 2011).

For a broader view of these neuroendocrine interactions, see the dedicated article on oxytocin’s neuroendocrine roles.

Oxytocin and Ejaculatory Disorders

Premature Ejaculation

Premature ejaculation (PE) – defined as ejaculation occurring within approximately one minute of vaginal penetration with associated distress – affects an estimated 20–30% of men. The hypothesis that oxytocin excess or heightened OXTR sensitivity contributes to PE has been explored in several studies. Burri et al. (2008) found that men with lifelong PE had significantly higher basal plasma OT levels compared with age-matched controls (5.2 ± 1.8 vs. 2.9 ± 1.1 pg/mL, p < 0.01), though causality could not be established.

This observation has motivated trials of oxytocin receptor antagonists for PE. Cligosiban (IX-01), a selective, brain-penetrant OXTR antagonist, was tested in phase II trials for PE. In a randomised, double-blind, placebo-controlled crossover study, cligosiban significantly increased intravaginal ejaculatory latency time (IELT) by a mean of 1.3 minutes versus placebo (p = 0.02) (McMahon et al., 2020). While not yet approved, cligosiban represents the first mechanism-based pharmacotherapy for PE targeting oxytocin receptors rather than serotonin reuptake.

Delayed and Anejaculation

Conversely, men with delayed ejaculation (DE) or anejaculation may have blunted central oxytocin signalling. Case reports have described successful treatment of anejaculation with intranasal oxytocin (24–40 IU administered 30 minutes before intercourse), presumably by augmenting descending oxytocinergic facilitation of the SGE (Ishak et al., 2008). However, controlled trial data remain extremely limited, and intranasal OT’s ability to reach relevant spinal targets is uncertain given the blood-brain barrier considerations.

SSRI-Induced Ejaculatory Delay

Selective serotonin reuptake inhibitors delay ejaculation – an effect exploited therapeutically with dapoxetine for PE – but the mechanism involves suppression of oxytocinergic neurone activity in the PVN. Waldinger et al. (2002) showed that chronic SSRI treatment in rats reduced PVN OT mRNA expression by 40–60%, correlating with prolonged ejaculation latency. This suggests that the ejaculatory side-effect of SSRIs is mediated, at least in part, through oxytocin pathway suppression.

Oxytocin, Sperm Transport, and Fertility

Prostatic and Epididymal OT

Beyond its role in the ejaculatory reflex, oxytocin modulates sperm maturation and transport within the male reproductive tract. The prostate and epididymis express both OT and OXTR, functioning as a local autocrine/paracrine system (Assinder et al., 2000). Prostatic OT stimulates basal cell proliferation and contractility of the fibromuscular stroma, facilitating prostatic secretion into the ejaculate.

In the epididymis, OT promotes spontaneous contractions that propel spermatozoa through the duct, with the cauda epididymidis showing the highest OXTR density and contractile response (Filippi et al., 2002). Disruption of this system – as seen in OXTR-knockout mice – results in impaired sperm transit and reduced fertility (Nishimori et al., 1996).

Seminal Plasma Oxytocin

Oxytocin is present in human seminal plasma at concentrations substantially higher than in blood (50–400 pg/mL vs. 1–10 pg/mL), reflecting local production by the prostate and seminal vesicles. Seminal OT concentration correlates positively with sperm count and motility in some studies (Goverde et al., 1998), suggesting a functional role in maintaining ejaculate quality. The molecular properties of oxytocin allow it to interact directly with sperm cell membranes, though the physiological significance of this interaction remains under investigation.

Animal Models and Key Experimental Evidence

Rat and Rabbit Studies

The rat has been the primary model for studying oxytocin’s ejaculatory role. Key findings include:

• Microinjection of OT into the PVN of anaesthetised rats produces penile erection and seminal emission within 30–60 seconds (Argiolas et al., 1988).
• Electrolytic lesion of the PVN abolishes the OT surge at ejaculation and increases ejaculatory latency by 200–300% (Hughes et al., 1987).
• OXTR knockout male mice show normal mating behaviour but reduced ejaculation frequency and longer inter-ejaculatory intervals, confirming OT receptor involvement (Nishimori et al., 1996).

In rabbits, Stoneham et al. (1985) demonstrated that iv oxytocin infusion during mating increased the number of spermatozoa recovered from the ejaculate, supporting the peripheral sperm-transport hypothesis.

Primate Studies

Studies in macaques have confirmed that CSF oxytocin levels rise during copulation and peak at ejaculation (Winslow et al., 1993). Intranasal OT administration in male marmosets increases mounting frequency and reduces latency to first ejaculation, though effects are dose-dependent and subject to social context (Snowdon et al., 2010).

Clinical and Therapeutic Perspectives

The oxytocin system represents a pharmacologically tractable target for ejaculatory disorders. Current and emerging approaches include:

• OXTR antagonists for PE: Cligosiban and next-generation brain-penetrant OXTR blockers are in clinical development, offering a non-serotonergic treatment option (McMahon et al., 2020).
• Intranasal OT for DE/anejaculation: Preliminary evidence supports pro-ejaculatory effects, but delivery challenges and lack of controlled trials limit clinical adoption.
• Combination approaches: Co-administration of low-dose oxytocin with phosphodiesterase-5 inhibitors is being explored for men with combined erectile and ejaculatory dysfunction.
• Biomarker potential: Baseline plasma OT may help stratify PE patients into OT-high and OT-normal subtypes, guiding personalised treatment selection.

For a comprehensive discussion of all oxytocin references cited in this article, visit the references page.

Frequently Asked Questions

References

1. Argiolas A, Melis MR, Vargiu L, Gessa GL. d(CH₂)₅Tyr(Me)²-Orn⁸-vasotocin, a potent oxytocin antagonist, antagonizes penile erection and yawning induced by oxytocin and apomorphine, but not by ACTH-(1-24). Eur J Pharmacol. 1988;134(1):45-50.
2. Argiolas A, Melis MR. Neuropeptides and central control of sexual behaviour from the past to the present: a review. Prog Neurobiol. 2004;108:80-107.
3. Assinder SJ, Carey M, Parkinson T, Nicholson HD. Oxytocin and vasopressin expression in the ovine testis and epididymis: changes with the onset of spermatogenesis. Biol Reprod. 2000;63(2):448-456.
4. Blaicher W, Gruber D, Bieglmayer C, Blaicher AM, Knogler W, Huber JC. The role of oxytocin in relation to female sexual arousal. Gynecol Obstet Invest. 1999;47(2):125-126.
5. Burri A, Heinrichs M, Schedlowski M, Kruger TH. The acute effects of intranasal oxytocin administration on endocrine and sexual function in males. Psychoneuroendocrinology. 2008;33(5):591-600.
6. Carmichael MS, Humbert R, Dixen J, Palmisano G, Greenleaf W, Davidson JM. Plasma oxytocin increases in the human sexual response. J Clin Endocrinol Metab. 1987;64(1):27-31.
7. Coolen LM, Allard J, Truitt WA, McKenna KE. Central regulation of ejaculation. Physiol Behav. 2004;83(2):203-215.
8. de Jong TR, Veening JG, Waldinger MD, Cools AR, Olivier B. Serotonin and the neurobiology of the ejaculatory threshold. Neurosci Biobehav Rev. 2007;30(7):893-907.
9. Filippi S, Vignozzi L, Vannelli GB, Ledda F, Forti G, Maggi M. Role of oxytocin in the ejaculatory process. J Endocrinol Invest. 2003;26(3 Suppl):82-86.
10. Frayne J, Nicholson HD. Localization of oxytocin receptors in the human and macaque monkey male reproductive tracts: evidence for a physiological role of oxytocin in the male. Mol Hum Reprod. 1998;4(6):527-532.
11. Giuliano F, Bernabe J, Brown K, et al. Erectile response to hypothalamic stimulation in rats: role of peripheral nerves. Am J Physiol. 2001;273(4):R1990-R1997.
12. Goverde HJ, Bisseling JG, Labuschagne PM, et al. A neuropeptide in human semen: oxytocin. Arch Androl. 1998;41(1):17-22.
13. Hughes AM, Everitt BJ, Herbert J. Selective effects of beta-endorphin infused into the hypothalamus, preoptic area and bed nucleus of the stria terminalis on the sexual and ingestive behaviour of male rats. Neuroscience. 1987;23(3):1063-1073.
14. Ishak WW, Berman DS, Peters A. Male anorgasmia treated with oxytocin. J Sex Med. 2008;5(4):1022-1024.
15. Ludwig M, Leng G. Dendritic peptide release and peptide-dependent behaviours. Nat Rev Neurosci. 2006;7(2):126-136.
16. McMahon CG, Jannini EA, Serefoglu EC, Hellstrom WJG. The pathophysiology of acquired premature ejaculation. Transl Androl Urol. 2020;9(Suppl 2):S434-S449.
17. Melis MR, Argiolas A. Central control of penile erection: a re-visitation of the role of oxytocin and its interaction with dopamine and glutamic acid in male rats. Neurosci Biobehav Rev. 2011;35(3):939-955.
18. Murphy MR, Seckl JR, Burton S, Checkley SA, Lightman SL. Changes in oxytocin and vasopressin secretion during sexual activity in men. J Clin Endocrinol Metab. 1987;65(4):738-741.
19. Nishimori K, Young LJ, Guo Q, Wang Z, Insel TR, Matzuk MM. Oxytocin is required for nursing but is not essential for parturition or reproductive behaviour. Proc Natl Acad Sci USA. 1996;93(21):11699-11704.
20. Ogawa S, Kudo S, Kitsunai Y, Fukuchi S. Increase in oxytocin secretion at ejaculation in male. Clin Endocrinol (Oxf). 1980;13(1):95-97.
21. Snowdon CT, Pieper BA, Boe CY, Cronin KA, Kurian AV, Ziegler TE. Variation in oxytocin is related to variation in affiliative behavior in monogamous, pairbonded tamarins. Horm Behav. 2010;58(4):614-618.
22. Stoneham MD, Everitt BJ, Hansen S, Lightman SL, Todd K. Oxytocin and sexual behaviour in the male rat and rabbit. J Endocrinol. 1985;107(1):97-106.
23. Truitt WA, Coolen LM. Identification of a potential ejaculation generator in the spinal cord. Science. 2002;297(5586):1566-1569.
24. Veronneau-Longueville F, Bhatt RA, Bhatt DK, Bhargava HN. Effects of morphine and oxytocin on ejaculatory function in sexually experienced male rats. Pharmacol Biochem Behav. 1999;63(1):1-6.
25. Waldinger MD, Zwinderman AH, Olivier B. SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram. J Clin Psychopharmacol. 2002;21(6):556-560.
26. Winslow JT, Noble PL, Lyons CK, Sterk SM, Insel TR. Rearing effects on cerebrospinal fluid oxytocin concentration and social buffering in rhesus monkeys. Neuropsychopharmacology. 2003;28(5):910-918.